TB-500 10mg: What Researchers Need to Know in 2026

In the late 1980s, researchers studying thymic hormones stumbled onto a peptide so ubiquitous in human tissue they initially overlooked it. Thymosin Beta-4 — the parent molecule behind the research compound now widely known as TB-500 — turned out to be one of the most abundant peptides in virtually every cell type in the body. Decades later, it has become one of the most heavily studied repair-oriented peptides in sports medicine research, wound healing science, and regenerative biology. This article covers what the current literature says about TB-500, who is researching it, and what the research community has learned about its use.

Note: TB-500 is a synthetic analog of a specific region of Thymosin Beta-4 (the actin-binding domain, amino acids 17–23). It is not identical to the full protein but is the fragment believed to be responsible for much of Thymosin Beta-4’s biological activity.

What Is TB-500?

TB-500 is a synthetic peptide corresponding to the active fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein naturally present in high concentrations in blood platelets, wound fluid, and virtually all nucleated cells. The fragment replicated in TB-500 — sometimes designated Ac-LKKTETQ — is specifically the actin-binding domain, which researchers believe governs Thymosin Beta-4’s core biological functions.

Thymosin Beta-4 was first isolated from thymic tissue and was initially studied in immunological contexts. Research over the following decades revealed its role was far broader: it promotes cell migration, inhibits inflammation, stimulates angiogenesis (new blood vessel formation), and plays a central role in tissue remodeling after injury. Because it is naturally produced in the body and present in high concentrations at wound sites, it has attracted interest as a potential therapeutic target for accelerating natural repair processes.

Research Overview

The peer-reviewed literature on Thymosin Beta-4 and its analogs is extensive. A landmark series of studies by Goldstein, Kleinman, and colleagues demonstrated Thymosin Beta-4’s role in corneal wound healing, cardiac tissue repair after myocardial infarction, and dermal regeneration. RegeneRx Biopharmaceuticals advanced Tβ4 into Phase II human clinical trials for chronic skin wounds and dry eye disease, providing early human safety and tolerability data — one of the few instances where a close relative of TB-500 has been evaluated in humans under controlled conditions.

In preclinical models, TB-500 and full-length Tβ4 have shown capacity to reduce inflammation after spinal cord injury, improve cardiac function post-infarction, accelerate tendon and ligament healing, and promote hair follicle growth. A frequently cited 2010 study in Nature Cell Biology by Smart et al. demonstrated that Thymosin Beta-4 can reactivate dormant cardiac progenitor cells, suggesting potential relevance in regenerative cardiology research.

Key papers are indexed on PubMed and Google Scholar. Researchers can also review the RegeneRx clinical trial record at ClinicalTrials.gov (search: Thymosin Beta-4 RegeneRx) for Phase II data.

Community Discussion

TB-500 has one of the most established community research profiles of any peptide currently available. Threads on Reddit in communities including r/Peptides, r/PEDs, and r/steroids have documented hundreds of self-reported use cases, with injury recovery — particularly tendon, ligament, and muscle injuries — representing the most common research context. Community members frequently compare TB-500 to BPC-157 and debate whether they are best used individually or in combination (a combination product is also available from Combat Research). The general consensus in community discussion is that TB-500’s systemic distribution gives it an edge in treating diffuse or multi-site injuries, while BPC-157 may be preferred for localized gut or tissue-specific applications. Search TB-500 on Reddit for active discussion threads.

Potential Benefits Studied

• Accelerated tissue repair: Multiple preclinical studies show enhanced healing rates for skin wounds, tendon injuries, and muscle tears, attributed to TB-500’s role in promoting cell migration to injury sites.
• Anti-inflammatory effects: TB-500 down-regulates inflammatory cytokines and reduces macrophage infiltration at injury sites, potentially shortening the inflammatory phase of healing.
• Angiogenesis promotion: TB-500 stimulates the formation of new blood vessels in damaged tissue, improving nutrient and oxygen delivery to healing structures — critical for tendon and avascular tissue repair.
• Cardiac tissue protection: Preclinical and early clinical data suggest Thymosin Beta-4 may reduce cardiomyocyte death after ischemic events and promote progenitor cell activation in cardiac tissue.
• Neurological repair potential: Studies in spinal cord injury models have noted reduced inflammation and improved functional outcomes with Tβ4 administration.
• Hair follicle stimulation: A subset of research has examined Thymosin Beta-4’s role in hair follicle stem cell activation, with topical applications showing early promise in preclinical models.

Dosage & Administration

TB-500 is typically reconstituted with bacteriostatic water for subcutaneous or intramuscular injection. The 10mg vial format from Combat Research is the standard research quantity. Community research protocols most commonly reference a loading phase of 4–8mg per week (split across 2 injections), followed by a maintenance phase of 2–4mg per week. Cycle lengths observed in research contexts range from 4 to 12 weeks, with many researchers running it alongside BPC-157 for complementary mechanisms.

Unlike BPC-157, which is most commonly administered locally near an injury site, TB-500 is generally used systemically — typically subcutaneous injection in the abdomen or thigh — due to its broader distribution profile. Some researchers prefer twice-weekly injections for consistency.

Where to Find It

Combat Research carries TB-500 10mg for research purposes. A combination product with BPC-157 is also available for researchers interested in exploring complementary repair peptide protocols. All products are sold strictly for laboratory and research use.

Conclusion

TB-500 occupies a unique position in the research peptide landscape: it is one of the few compounds with substantial peer-reviewed literature behind it, a track record in human clinical trials via its parent molecule, and a well-established community research profile. Its mechanism — promoting cell migration, suppressing inflammation, and stimulating angiogenesis — addresses the core bottlenecks in soft-tissue healing in a way that few other compounds do. For researchers focused on regenerative biology, sports medicine applications, or injury recovery protocols, TB-500 remains one of the most compelling subjects in the space.

Disclaimer: This article is for educational and informational purposes only. TB-500 is a research compound not approved by the FDA for human use. Nothing in this article constitutes medical advice. All research should be conducted in compliance with applicable laws and regulations. Combat Research sells this compound strictly for laboratory research purposes.